EXELIXIS, INC.

Exelixis, Inc. (NASDAQ: EXEL) is an oncology company focused on innovating next-generation medicines and regimens at the forefront of cancer care. The company develops and commercializes targeted therapies and biotherapeutics designed to treat various forms of cancer through small molecule inhibitors and antibody-drug conjugates. More information about the company can be found at www.exelixis.com.

The company's revenue is primarily generated from its marketed pharmaceutical products, with cabozantinib-based therapies representing the substantial majority of sales. Cabozantinib is formulated and marketed under two brand names: CABOMETYX tablets and COMETRIQ capsules. CABOMETYX is approved by the FDA and regulatory authorities in 68 countries for multiple indications including advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors. COMETRIQ is approved for progressive medullary thyroid cancer. The company also markets COTELLIC, a MEK inhibitor developed in collaboration with Genentech for advanced melanoma, and MINNEBRO, a mineralocorticoid receptor antagonist licensed to Daiichi Sankyo for hypertension treatment in Japan.

Outside the United States, Exelixis relies on collaboration partners for cabozantinib commercialization, with Ipsen responsible for all territories outside the U.S. and Japan, and Takeda handling the Japanese market. The company generates royalties from these partnerships in addition to direct U.S. product revenues.

Exelixis maintains an extensive clinical development pipeline advancing multiple programs. Zanzalintinib, the company's lead clinical asset, is a novel oral kinase inhibitor currently under FDA review for colorectal cancer and being evaluated across multiple indications including renal cell carcinoma, neuroendocrine tumors, and meningioma. The company is also developing several biotherapeutic candidates in phase 1 development, including XL309, an inhibitor of USP1 for BRCA-mutated tumors; XB010, an antibody-drug conjugate targeting 5T4; XB628, a bispecific antibody targeting PD-L1 and NKG2A; and XB371, a tissue factor-targeting antibody-drug conjugate.

The company has established itself as a profitable oncology enterprise through disciplined investment in its pipeline while maintaining strong cash generation from its marketed products.